CIPLA LTDShort
wait for correction to complete
Updated
Hello,
Cipla Ltd. engages in the manufacture and distribution of healthcare products and bulk drugs. It operates through the following segments: Pharmaceuticals and New Ventures. The Pharmaceuticals segment develops, manufactures, sells and distributes generic or branded generic medicines as well as active pharmaceutical ingredients.
Below a few metrics we look at
Market cap: 729Bllion Indian rupees
EPS: 32.7INR
Revenues: 2021(217B INR)
Net revenues: 2021 (25.17B INR)
Total assets: 2021 (251.52B)
Total labilities: 2021 (65.6B)
Free cashflow : 30.67
More information of this company can be found on its website cipla.com/investors
Do your own research before taking this trades.
Good luck!
Cipla Ltd. engages in the manufacture and distribution of healthcare products and bulk drugs. It operates through the following segments: Pharmaceuticals and New Ventures. The Pharmaceuticals segment develops, manufactures, sells and distributes generic or branded generic medicines as well as active pharmaceutical ingredients.
Below a few metrics we look at
Market cap: 729Bllion Indian rupees
EPS: 32.7INR
Revenues: 2021(217B INR)
Net revenues: 2021 (25.17B INR)
Total assets: 2021 (251.52B)
Total labilities: 2021 (65.6B)
Free cashflow : 30.67
More information of this company can be found on its website cipla.com/investors
Do your own research before taking this trades.
Good luck!
Note
Note
For personalized investment advisory services
Reach me on email hesbonmose001@gmail.com to join paid premium group. (one off $60 to join)
Free in-depth stock markets analysis Telegram channel: t.me/stocksfromtechnicaleye
Reach me on email hesbonmose001@gmail.com to join paid premium group. (one off $60 to join)
Free in-depth stock markets analysis Telegram channel: t.me/stocksfromtechnicaleye
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.